Stoke Therapeutics' CMO Offloads More Than 5,000 Shares: Is It Time for Shareholders to Sell?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Should l Buy STOK?
Source: NASDAQ.COM
Insider Stock Sale: Barry Ticho, Chief Medical Officer of Stoke Therapeutics, sold 5,358 shares for approximately $167,115, reducing his direct ownership to 19,798 shares, which is 0.0347% of the company's outstanding shares.
Reason for Sale: The stock sale was part of an option exercise and was not indicative of negative sentiment, as Ticho still holds nearly 20,000 shares and the transaction was likely a strategic move to capitalize on the stock's price appreciation.
Company Performance: Stoke Therapeutics has seen a significant increase in stock price due to positive clinical trial results for its lead drug candidate and strong financial performance, reporting $328.6 million in cash and $183 million in revenue year-to-date.
Market Outlook: Analysts suggest that Ticho's stock sales should not alarm shareholders, as the company's solid financial position is expected to support operations until 2028, indicating a positive business trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STOK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STOK
Wall Street analysts forecast STOK stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.990
Low
25.00
Averages
35.75
High
50.00
Current: 31.990
Low
25.00
Averages
35.75
High
50.00
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chair of Stoke Therapeutics Sells Shares
- Share Sale Details: Arthur Tzianabos, chair of Stoke Therapeutics, disclosed the sale of 4,355 shares on March 10, 2026, for approximately $174,000 at an average price of $40 per share, reducing his direct holdings by 12.20% to 31,339 shares, indicating a significant decrease in ownership.
- Options Exercise Context: This sale followed the exercise of 3,955 options, with all shares sold coming from direct holdings and no indirect entities involved, although Tzianabos retains a substantial number of additional options, reflecting ongoing confidence in the company's future prospects.
- Clinical Progress Support: Stoke recently advanced STK-002 into a Phase 1 study for autosomal dominant optic atrophy, expanding its pipeline, and data published in The New England Journal of Medicine indicated that the lead candidate, zorevunersen, shows potential disease-modifying effects for Dravet syndrome, making future clinical data performance critical for valuation.
- Investor Considerations: While option-driven selling among executives typically reflects compensation structures rather than sentiment changes, for long-term investors, the focus should be on the reliability of future clinical data and its potential for regulatory approval, which will directly impact the company's future returns.
See More
Stoke Therapeutics Chair Sells 4,355 Shares of Stock
- Transaction Overview: Arthur Tzianabos, chair of Stoke Therapeutics, sold 4,355 shares of common stock on March 10, 2026, for approximately $174,000, indicating a liquidity need within his equity compensation structure.
- Ownership Change Analysis: This sale reduced Tzianabos's direct common stock holdings by 12.20% to 31,339 shares; however, he retains 118,696 stock options, suggesting significant potential future ownership remains intact.
- Market Performance & Company Overview: Stoke Therapeutics boasts a market capitalization of $1.9 billion, with a remarkable 340% price increase over the past year, primarily driven by its development of antisense oligonucleotide medicines targeting severe genetic diseases, showcasing its competitive edge in biotechnology.
- Clinical Progress & Investor Outlook: The company recently advanced STK-002 into a Phase 1 study for autosomal dominant optic atrophy, and data published in The New England Journal of Medicine highlighted significant efficacy for its lead candidate, indicating that future clinical data will be crucial for investor returns.
See More
Stoke Therapeutics Chair Sells Shares Worth $174K Amid 340% Stock Surge
- Transaction Overview: Arthur Tzianabos, Chair of Stoke Therapeutics, sold 4,355 shares of common stock on March 10, 2026, for approximately $174,000, indicating a liquidity need amidst a 340% stock price surge.
- Ownership Change Analysis: This sale reduced Tzianabos's direct common stock holdings by 12.20% to 31,339 shares; however, he retains 118,696 stock options, suggesting significant potential future ownership.
- Market Reaction and Outlook: While option-driven selling among executives typically reflects compensation structures rather than sentiment shifts, Stoke Therapeutics has shown strong clinical progress, particularly with STK-002 entering Phase 1 trials, which may support future growth.
- Investor Focus: For long-term investors, the key takeaway lies in the ongoing performance of clinical data and the likelihood of regulatory approval, rather than the isolated stock sale, as these factors will directly influence future returns.
See More
Stoke Therapeutics Executive Sells Shares Amid Strong Performance
- Executive Stock Sale: Barry Ticho, Chief Medical Officer of Stoke Therapeutics, sold 14,311 shares of common stock for approximately $457,000 between March 17 and March 19, 2026, indicating a significant change in his holdings.
- Ownership Change: Following the transaction, Ticho's direct ownership decreased from 55,013 shares to 40,702 shares, a 26.01% reduction, while he retains 83,035 stock options, maintaining substantial future conversion potential.
- Transaction Context: The sale was executed following the exercise of options and is notably larger than the recent median sale size of 5,429.5 shares, reflecting an atypical disposition of his holdings compared to historical trading activity.
- Market Outlook: Despite the insider sale, Stoke Therapeutics has seen its stock price rise approximately 300% over the past year, and the company is advancing its RNA-based platform targeting severe genetic diseases, making future clinical data performance crucial for investors.
See More
Stoke Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: On March 16, 2026, Stoke Therapeutics granted stock options for a total of 58,650 shares to six new employees as a material inducement for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Set: The granted stock options have an exercise price of $33.96 per share, which matches the closing price of Stoke's common stock on March 16, 2026, ensuring that employees are incentivized at a stable market price.
- Vesting Schedule: Each option will vest over a four-year period, with one-quarter of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining shares vesting monthly over the following 36 months, promoting employee retention.
- Long-Term Incentive Plan: The options have a term of 10 years and are subject to the terms of the 2023 Inducement Plan and the stock option agreement, aiming to attract and retain talent through a long-term incentive mechanism.
See More
Stoke and Biogen Release Zorevunersen Study Data
- Study Results Released: Stoke Therapeutics and Biogen announced the publication of data on the investigational drug Zorevunersen, indicating its potential for disease modification in patients with Dravet syndrome, marking a significant advancement in treatment options.
- Clinical Trial Data: Results from two completed Phase 1/2a trials and ongoing open-label extension studies demonstrated substantial and durable reductions in seizures, along with improvements across multiple cognitive and behavioral measures, indicating long-term efficacy.
- Future Research Outlook: Barry Ticho, Chief Medical Officer of Stoke, stated that Zorevunersen could become the first disease-modifying medicine for Dravet syndrome, with anticipation for the Phase 3 EMPEROR study results expected in mid-2027 to further validate its efficacy.
- Market Reaction: Stoke shares closed at $34.42 on Nasdaq, up 1.89%, reflecting positive market expectations regarding the drug's potential.
See More
Chair of Stoke Therapeutics Sells Shares
- Share Sale Details: Arthur Tzianabos, chair of Stoke Therapeutics, disclosed the sale of 4,355 shares on March 10, 2026, for approximately $174,000 at an average price of $40 per share, reducing his direct holdings by 12.20% to 31,339 shares, indicating a significant decrease in ownership.
- Options Exercise Context: This sale followed the exercise of 3,955 options, with all shares sold coming from direct holdings and no indirect entities involved, although Tzianabos retains a substantial number of additional options, reflecting ongoing confidence in the company's future prospects.
- Clinical Progress Support: Stoke recently advanced STK-002 into a Phase 1 study for autosomal dominant optic atrophy, expanding its pipeline, and data published in The New England Journal of Medicine indicated that the lead candidate, zorevunersen, shows potential disease-modifying effects for Dravet syndrome, making future clinical data performance critical for valuation.
- Investor Considerations: While option-driven selling among executives typically reflects compensation structures rather than sentiment changes, for long-term investors, the focus should be on the reliability of future clinical data and its potential for regulatory approval, which will directly impact the company's future returns.
See More
Stoke Therapeutics Chair Sells 4,355 Shares of Stock
- Transaction Overview: Arthur Tzianabos, chair of Stoke Therapeutics, sold 4,355 shares of common stock on March 10, 2026, for approximately $174,000, indicating a liquidity need within his equity compensation structure.
- Ownership Change Analysis: This sale reduced Tzianabos's direct common stock holdings by 12.20% to 31,339 shares; however, he retains 118,696 stock options, suggesting significant potential future ownership remains intact.
- Market Performance & Company Overview: Stoke Therapeutics boasts a market capitalization of $1.9 billion, with a remarkable 340% price increase over the past year, primarily driven by its development of antisense oligonucleotide medicines targeting severe genetic diseases, showcasing its competitive edge in biotechnology.
- Clinical Progress & Investor Outlook: The company recently advanced STK-002 into a Phase 1 study for autosomal dominant optic atrophy, and data published in The New England Journal of Medicine highlighted significant efficacy for its lead candidate, indicating that future clinical data will be crucial for investor returns.
See More
Stoke Therapeutics Chair Sells Shares Worth $174K Amid 340% Stock Surge
- Transaction Overview: Arthur Tzianabos, Chair of Stoke Therapeutics, sold 4,355 shares of common stock on March 10, 2026, for approximately $174,000, indicating a liquidity need amidst a 340% stock price surge.
- Ownership Change Analysis: This sale reduced Tzianabos's direct common stock holdings by 12.20% to 31,339 shares; however, he retains 118,696 stock options, suggesting significant potential future ownership.
- Market Reaction and Outlook: While option-driven selling among executives typically reflects compensation structures rather than sentiment shifts, Stoke Therapeutics has shown strong clinical progress, particularly with STK-002 entering Phase 1 trials, which may support future growth.
- Investor Focus: For long-term investors, the key takeaway lies in the ongoing performance of clinical data and the likelihood of regulatory approval, rather than the isolated stock sale, as these factors will directly influence future returns.
See More
Stoke Therapeutics Executive Sells Shares Amid Strong Performance
- Executive Stock Sale: Barry Ticho, Chief Medical Officer of Stoke Therapeutics, sold 14,311 shares of common stock for approximately $457,000 between March 17 and March 19, 2026, indicating a significant change in his holdings.
- Ownership Change: Following the transaction, Ticho's direct ownership decreased from 55,013 shares to 40,702 shares, a 26.01% reduction, while he retains 83,035 stock options, maintaining substantial future conversion potential.
- Transaction Context: The sale was executed following the exercise of options and is notably larger than the recent median sale size of 5,429.5 shares, reflecting an atypical disposition of his holdings compared to historical trading activity.
- Market Outlook: Despite the insider sale, Stoke Therapeutics has seen its stock price rise approximately 300% over the past year, and the company is advancing its RNA-based platform targeting severe genetic diseases, making future clinical data performance crucial for investors.
See More
Stoke Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: On March 16, 2026, Stoke Therapeutics granted stock options for a total of 58,650 shares to six new employees as a material inducement for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Set: The granted stock options have an exercise price of $33.96 per share, which matches the closing price of Stoke's common stock on March 16, 2026, ensuring that employees are incentivized at a stable market price.
- Vesting Schedule: Each option will vest over a four-year period, with one-quarter of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining shares vesting monthly over the following 36 months, promoting employee retention.
- Long-Term Incentive Plan: The options have a term of 10 years and are subject to the terms of the 2023 Inducement Plan and the stock option agreement, aiming to attract and retain talent through a long-term incentive mechanism.
See More
Stoke and Biogen Release Zorevunersen Study Data
- Study Results Released: Stoke Therapeutics and Biogen announced the publication of data on the investigational drug Zorevunersen, indicating its potential for disease modification in patients with Dravet syndrome, marking a significant advancement in treatment options.
- Clinical Trial Data: Results from two completed Phase 1/2a trials and ongoing open-label extension studies demonstrated substantial and durable reductions in seizures, along with improvements across multiple cognitive and behavioral measures, indicating long-term efficacy.
- Future Research Outlook: Barry Ticho, Chief Medical Officer of Stoke, stated that Zorevunersen could become the first disease-modifying medicine for Dravet syndrome, with anticipation for the Phase 3 EMPEROR study results expected in mid-2027 to further validate its efficacy.
- Market Reaction: Stoke shares closed at $34.42 on Nasdaq, up 1.89%, reflecting positive market expectations regarding the drug's potential.
See More
